Companies working on new injectable asthma medication

There is a major potential market of people who do not control their asthma well.

There is a new race among allergy medication companies to tap into a potential multi-billion dollar industry: injectable biotech asthma drugs. This new kind of medication technology would be used for people who severely suffer from the breathing affliction but do not respond well to the traditional inhalers that already exist. Experts estimate that this new market would be worth at least $8 billion globally.

There are several massive companies – such as GlaxoSmithKline, Roche, AstraZeneca and Teva – that are working to create this new medication delivery system and get it safely onto the market first. Despite the advancements in asthma treatment over the last several decades, health officials estimate that 20 percent of those on standard therapy do not have their asthma under control. In industrialized nations, this is as many as two million people who are not adequately managing their asthma.

This new kind of injectable asthma medication will be more effective at treating an attack, according to several doctors who are leading the studies. The existing methods of treating asthma force the airway to open up to allow the person to breathe, while this new method would directly target the chemicals that are present in the body that set off the asthma in the first place.

Of course, this new medication delivery system is still being tested and is not yet available to the general public. If you suffer from asthma and are looking for ways to manage your symptoms, the best way to start is to eliminate potential triggers in your home. Invest in a home air purifier from US Air Purifiers Direct 2U today!